Tag: ICRA
Indian hospital industry to post robust performance in FY2023: ICRA
Aggregate occupancy for the sample set is estimated at 62-64% for FY2023. With ARPOB growth expected at 8-10% on a YoY basis, translating to 15-17% revenue growth
Pricing pressures & regulatory overhang affect margins of Indian pharma companies...
Continued pricing pressures in the US and European markets and cost inflation likely to result in 50-100 bps contraction in operating profit margin for ICRA’s sample set in FY2023
Outlook for the Indian pharma industry remains stable: ICRA
Continued pricing pressures in the US and European markets and cost inflation likely to result in 120-150 bps contraction in operating profit margin for ICRA sample set in FY2023
Revenue growth of hospitals to be moderate in FY2023: ICRA study
Aggregate occupancy for the sample set to be ~60-62% in FY2023; on a YoY basis, given the high base of FY2022, this translates to revenue growth of over 12%
Indian pharma companies to grow by 6-7% in FY2023: ICRA study
Headwinds related to pricing pressures in the US generics market and rising raw material costs will result in contraction of sample set profit margins in FY2023
Omicron hits elective surgeries, yet hospitals to report robust revenue in...
Given the relatively higher transmissibility of Omicron, large number of healthcare workers have also been infected with Covid-19 which might impact hospital operations to a certain extent
Diagnostic players to deliver double-digit revenue growth in FY2022: ICRA
ICRA predicts that prices of diagnostic tests are likely to stabilize at current levels due to focus on volume growth and higher competitive intensity from unorganized players
Hospitals expected to report 20-22% revenue growth in FY2022: ICRA
Occupancies likely to improve to 61-63% in FY2022, from 52.5% in FY2021 due to higher hospitalisations on account of second wave of Covid-19 and YoY increase in number of elective procedures owing to less restrictive lockdown as well as higher vaccination coverage.....................
ECLGS 4.0 to support capacity creation in healthcare: ICRA
Removal of the Rs. 500 crore-cap of loan outstanding for eligibility under ECLGS 3.0 provides access to larger healthcare companies for creating additional capacities..........................
RBI’s INR 50,000 crore liquidity window to boost healthcare infrastructure: ICRA
Loan tenor being capped at three years could be an impediment in availing the facility given that most industry players have a relatively longer asset pay-back period..........................